Meeting of the Advisory Council for the Elimination of Tuberculosis, 41440-41441 [2024-10300]
Download as PDF
<![CDATA[
41440
Federal Register / Vol. 89, No. 93 / Monday, May 13, 2024 / Notices
have not been modified include CBC,
hemoglobin variants, HIV, cadmium,
and lead. RBC folate forms, LDC
cholesterol, and chlamydia are
examples of tests that have been
removed for 2025–2026. New laboratory
tests include B vitamins, choline and
metabolites, and aldosterone. The
biospecimens collected for laboratory
tests include urine and blood. Serum,
plasma, DNA, and urine specimens will
be stored for future testing if the
participant provides consent.
and children tend to have shorter
interviews and exams than adults. This
is because young people may have fewer
health conditions or medications to
report so their interviews take less time
or because certain exams are only
conducted on sample persons 18 and
older. In addition, adults often serve as
proxy respondents for young people in
their families. Participation in NHANES
is voluntary and confidential. The
Program is requesting a three-year
approval, with 36,540 annualized hours
of burden in this clearance request.
NHANES may conduct developmental
projects during NHANES 2025–2026,
with a focus on planning for NHANES
2027 and beyond. These may include
activities such as tests of new
equipment, crossover studies between
current and proposed methods, test of
different study modes, settings or
technology, outreach materials,
incentive strategies, sample storage and
processing or sample designs.
Burden for individuals in 2025–2026
NHANES will vary based on their level
of participation. For example, infants
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondents
Individuals
Individuals
Individuals
Individuals
in
in
in
in
households
households
households
households
..................
..................
..................
..................
Individuals in households ..................
Individuals in households ..................
Total ...........................................
1
1
1
1
7/60
1
2
1
747
5,882
10,000
5,882
5,882
1
36/60
3,529
3,500
1
3
10,500
...........................................................
........................
........................
........................
36,540
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Meeting of the Advisory Council for the
Elimination of Tuberculosis
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
AGENCY:
Notice of meeting.
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC) announces the
following meeting of the Advisory
Council for the Elimination of
Tuberculosis (ACET). This meeting is
open to the public, limited only by the
number of audio and web conference
lines (1,000 lines are available). Time
will be available for public comment
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
21:33 May 10, 2024
Total burden
(in hours)
6,398
5,882
5,000
5,882
[FR Doc. 2024–10357 Filed 5–10–24; 8:45 am]
VerDate Sep<11>2014
Average
burden per
response
(in hours)
Number of
responses per
respondent
Screener ...........................................
Home Interview ................................
MEC Interview & Examination .........
Day 1 Telephone Dietary Recall, Dietary Supplements, & Flexible
Consumer Behavior Survey
Phone Follow-up.
Day 2 Telephone Dietary Recall &
Dietary Supplements.
Developmental Projects & Special
Studies.
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
ACTION:
Number of
respondents
Form name
Jkt 262001
(registration is required to provide oral
comment).
DATES: The meeting will be held on June
25, 2024, from 9:30 a.m. to 4:30 p.m.,
EDT, and June 26, 2024, from 10 a.m. to
12 p.m., EDT.
Written comments must be submitted
by July 2, 2024. Registration to make
oral comments must be submitted by
June 18, 2024.
ADDRESSES: The telephone access
number is 1–669–254–5252, Webinar
ID: 160 567 2365, and the Passcode is
53696016. The web conference access is
https://cdc.zoomgov.com/j/
1605672365?pwd=Vjd0N0JIdjR
3ZTZUZ21kaTcvMHVTZz09, and the
Passcode is 9?A=EB8b. The number of
available audio and web conference
lines is 1,000.
FOR FURTHER INFORMATION CONTACT:
Marah Condit, M.S., Committee
Management Lead, Office of Policy,
Planning, and Partnerships, National
Center for HIV, Viral Hepatitis, STD,
and TB Prevention, Centers for Disease
Control and Prevention, 1600 Clifton
Road NE, Mailstop US8–6, Atlanta,
Georgia 30329–4027. Telephone: (404)
639–3423; Email: nchhstppolicy@
cdc.gov.
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
Purpose: The Advisory Council for
the Elimination of Tuberculosis is
charged with providing advice and
recommendations regarding the
elimination of tuberculosis (TB) to the
Secretary of Health and Human
Services, the Assistant Secretary for
Health, and the Director, Centers for
Disease Control and Prevention (CDC).
Specifically, the Council makes
recommendations regarding policies,
strategies, objectives, and priorities;
addresses the development and
application of new technologies;
provides guidance and review on CDC’s
Tuberculosis Prevention Research
portfolio and program priorities; and
reviews the extent to which progress has
been made toward eliminating TB.
Matters to be Considered: The agenda
will include discussions on: (1) CDC’s
National Center for HIV, Viral Hepatitis,
STD, and TB Prevention Update; (2)
CDC’s Division of Tuberculosis
Elimination Update; (3) TB in New
Arrivals; (4) Regulation of Laboratory
Developed Tests and the Impact on TB
Testing in the United States; (5)
National Tuberculosis Coalition of
America Guidelines for Respiratory
Isolation and Restrictions to Reduce
Transmission of Pulmonary
Tuberculosis in Community Settings; (6)
E:\FR\FM\13MYN1.SGM
13MYN1
Federal Register / Vol. 89, No. 93 / Monday, May 13, 2024 / Notices
Laboratory Developed Tests Workgroup
Update; and (7) Drug Shortage
Workgroup Update. Agenda items are
subject to change as priorities dictate.
Public Participation
Written Public Comment: Members of
the public are welcome to submit
written comments in advance of the
meeting. Written comments must be
submitted by emailing nchhstppolicy@
cdc.gov with subject line ‘‘ACET June
2024 Public Comment Registration’’ by
July 2, 2024.
Oral Public Comment: Individuals
who would like to make an oral
comment during the public comment
period must register by emailing
nchhstppolicy@cdc.gov with subject
line ‘‘ACET June 2024 Public Comment
Registration’’ by June 18, 2024. The
public comment period is on June 26,
2024, at 10:15 a.m., EDT.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–10300 Filed 5–10–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–24–23HS]
lotter on DSK11XQN23PROD with NOTICES1
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘National
Survey of Syringe Services Programs
(NSSSP)’’, to the Office of Management
and Budget (OMB) for review and
approval. CDC previously published a
‘‘Proposed Data Collection Submitted
for Public Comment and
Recommendations’’ notice on May 4,
2023, to obtain comments from the
public and affected agencies. CDC
received two public comments related
to the previous notice. This notice
VerDate Sep<11>2014
21:33 May 10, 2024
Jkt 262001
serves to allow an additional 30 days for
public and affected agency comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Program Evaluation for PS22–2208
Component 2—New—National Center
for HIV, Viral Hepatitis, STD, and TB
Prevention (NCHHSTP), Centers for
Disease Control and Prevention, Centers
for Disease Control and Prevention
(CDC).
Background and Brief Description
PS22–2208 Component 2
(Strengthening Syringe Services
Programs) serves as a coordinated and
accountable mechanism for distribution
of funding to syringe services programs
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
41441
(SSPs) to support implementation and
expansion of services in areas of the
United States, Territories, and Tribal
Nations disproportionately affected by
infectious disease consequences of
injection drug use. Project activities will
directly contribute to establishing and
expanding a national SSP infrastructure
and prevention of infectious disease
consequences of drug use. CDC has
funded the National Alliance of State
and Territorial AIDs Directors
(NASTAD) to implement this project.
NASTAD, in partnership with
University of Washington will collect
monitoring and evaluation data from
funded SSPs through their internal
mechanisms, both for their internal
evaluation as well as to report semiannual and annual project performance
reports and stratified aggregate data to
CDC. The primary purpose of this
information collection is to monitor and
evaluate the PS22–2208 Component 2
funding opportunity’s overall goal of
supporting SSP subrecipients in
meeting the needs of people who use
drugs (PWUD) and reducing infectious
disease and other harms related to drug
use.
During the first year of this
Cooperative Agreement, all PS22–2208
SSP subrecipients will be sent a 25minute baseline program evaluation
survey at the start of project
implementation, and a 15-minute
quarterly program evaluation survey in
the following three quarters of the
project period. For Years 2–5, new
PS22–2208 SSP subrecipients will be
sent the baseline survey at the start of
project implementation, and all existing
subrecipients will receive the quarterly
program evaluation survey in the
following three quarters of the project
period. SSP subrecipients will primarily
complete the survey online in REDCap,
with options to complete via telephone
or videoconferencing modalities.
Subrecipients will be asked to complete
the surveys within one month of receipt
and will receive weekly reminders until
the survey is complete. SSP
subrecipients may be reminded
informally during meetings with
NASTAD and may also work with their
NASTAD point-of-contact to determine
an alternate method of survey
completion. The survey will include
questions on operational and
programmatic characteristics, and
quantity of prevention and treatment
services provided in-person, through
tele-health, and through navigation to
off-site care, during the specified
evaluation period.
Approximately 200 SSPs will
participate in the survey. We estimate
that it will take 70 minutes for each SSP
E:\FR\FM\13MYN1.SGM
13MYN1
]]>Agencies
[Federal Register Volume 89, Number 93 (Monday, May 13, 2024)]
[Notices]
[Pages 41440-41441]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-10300]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Meeting of the Advisory Council for the Elimination of
Tuberculosis
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the
Centers for Disease Control and Prevention (CDC) announces the
following meeting of the Advisory Council for the Elimination of
Tuberculosis (ACET). This meeting is open to the public, limited only
by the number of audio and web conference lines (1,000 lines are
available). Time will be available for public comment (registration is
required to provide oral comment).
DATES: The meeting will be held on June 25, 2024, from 9:30 a.m. to
4:30 p.m., EDT, and June 26, 2024, from 10 a.m. to 12 p.m., EDT.
Written comments must be submitted by July 2, 2024. Registration to
make oral comments must be submitted by June 18, 2024.
ADDRESSES: The telephone access number is 1-669-254-5252, Webinar ID:
160 567 2365, and the Passcode is 53696016. The web conference access
is https://cdc.zoomgov.com/j/1605672365?pwd=Vjd0N0JIdjR3ZTZUZ21kaTcvMHVTZz09, and the Passcode is
9?A=EB8b. The number of available audio and web conference lines is
1,000.
FOR FURTHER INFORMATION CONTACT: Marah Condit, M.S., Committee
Management Lead, Office of Policy, Planning, and Partnerships, National
Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for
Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US8-6,
Atlanta, Georgia 30329-4027. Telephone: (404) 639-3423; Email:
[email protected].
SUPPLEMENTARY INFORMATION:
Purpose: The Advisory Council for the Elimination of Tuberculosis
is charged with providing advice and recommendations regarding the
elimination of tuberculosis (TB) to the Secretary of Health and Human
Services, the Assistant Secretary for Health, and the Director, Centers
for Disease Control and Prevention (CDC). Specifically, the Council
makes recommendations regarding policies, strategies, objectives, and
priorities; addresses the development and application of new
technologies; provides guidance and review on CDC's Tuberculosis
Prevention Research portfolio and program priorities; and reviews the
extent to which progress has been made toward eliminating TB.
Matters to be Considered: The agenda will include discussions on:
(1) CDC's National Center for HIV, Viral Hepatitis, STD, and TB
Prevention Update; (2) CDC's Division of Tuberculosis Elimination
Update; (3) TB in New Arrivals; (4) Regulation of Laboratory Developed
Tests and the Impact on TB Testing in the United States; (5) National
Tuberculosis Coalition of America Guidelines for Respiratory Isolation
and Restrictions to Reduce Transmission of Pulmonary Tuberculosis in
Community Settings; (6)
[[Page 41441]]
Laboratory Developed Tests Workgroup Update; and (7) Drug Shortage
Workgroup Update. Agenda items are subject to change as priorities
dictate.
Public Participation
Written Public Comment: Members of the public are welcome to submit
written comments in advance of the meeting. Written comments must be
submitted by emailing [email protected] with subject line ``ACET
June 2024 Public Comment Registration'' by July 2, 2024.
Oral Public Comment: Individuals who would like to make an oral
comment during the public comment period must register by emailing
[email protected] with subject line ``ACET June 2024 Public Comment
Registration'' by June 18, 2024. The public comment period is on June
26, 2024, at 10:15 a.m., EDT.
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-10300 Filed 5-10-24; 8:45 am]
BILLING CODE 4163-18-P
